Zalypsis | 308359-57-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Zalypsis
• 英文别名: [(1R,2S,13R,15S,16S)-15,22-dihydroxy-21-methoxy-6,20,24-trimethyl-13-[[[(E)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl]amino]methyl]-8,10-dioxa-14,24-diazahexacyclo[14.7.1.02,14.04,12.07,11.018,23]tetracosa-4,6,11,18(23),19,21-hexaen-5-yl] acetate
• CAS: 308359-57-1
• 化学式: C₃₇H₃₈F₃N₃O₈
• 分子量: 709.7
• InChiKey: VPAHZSUNBOYNQY-DLVGLDQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  51
• 可旋转键数：
  7
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  13

文献信息

• [EN] FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS<br/>[FR] LIGANDS DE PROTÉINE D'ACTIVATION DES FIBROBLASTES POUR APPLICATIONS D'ADMINISTRATION CIBLÉE
  申请人：PHILOCHEM AG

  公开号：WO2021160825A1

  公开（公告）日：2021-08-19

  The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g. cytotoxic drugs, radionuclides, fluorophores, proteins and immunomodulators) at the site of disease. In particular, the present invention relates to the development of FAP ligands for targeting applications, in particular diagnostic methods and/or methods for therapy or surgery in relation to a disease or disorder, such as cancer, inflammation or another disease characterized by overexpression of FAP.

  本发明涉及纤维母细胞活化蛋白（FAP）的配体，用于在疾病部位主动传递各种有效载荷（例如细胞毒药物、放射性核素、荧光染料、蛋白质和免疫调节剂）。具体而言，本发明涉及开发用于靶向应用的FAP配体，特别是用于诊断方法和/或与疾病或疾病相关的治疗或手术方法，如癌症、炎症或另一种以FAP过表达为特征的疾病。
• Combination therapy with an antitumor alkaloid
  申请人：Pharma Mar S.A.

  公开号：EP2786754A2

  公开（公告）日：2014-10-08

  The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM001 04, and the use of these combinations in the treatment of cancer.

  本发明涉及PM01183与多种抗癌药物的组合，特别是选自抗肿瘤铂配位络合物、抗代谢物、有丝分裂抑制剂、抗癌抗生素、拓扑异构酶I和/或II抑制剂、蛋白酶体抑制剂、组蛋白去乙酰化酶抑制剂的其他抗癌药物、氮芥烷化剂、亚硝基脲烷化剂、非经典烷化剂、雌激素拮抗剂、雄激素拮抗剂、mTOR 抑制剂、酪氨酸激酶抑制剂，以及选自 aplidine、ET-743、PM02734 和 PM001 04 的其他制剂，以及这些组合在癌症治疗中的应用。
• FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
  申请人：Philochem AG

  公开号：EP4019507A1

  公开（公告）日：2022-06-29

  The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g. cytotoxic drugs, radionuclides, fluorophores, proteins and immunomodulators) at the site of disease. In particular, the present invention relates to the development of FAP ligands for targeting applications, in particular diagnostic methods and/or methods for therapy or surgery in relation to a disease or disorder, such as cancer, inflammation or another disease characterized by overexpression of FAP.

  本发明涉及成纤维细胞活化蛋白(FAP)的配体，用于将各种有效载荷(如细胞毒性药物、放射性核素、荧光团、蛋白质和免疫调节剂)主动输送到疾病部位。特别是，本发明涉及开发用于靶向应用的 FAP 配体，尤其是与癌症、炎症或其他以 FAP 过度表达为特征的疾病或紊乱有关的诊断方法和/或治疗或手术方法。
• FORMULATIONS COMPRISING JORUMYCIN-, RENIERAMYCIN-, SAFRACIN- OR SAFRAMYCIN-RELATED COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES
  申请人：Calvo Salve Pilar

  公开号：US20090076016A1

  公开（公告）日：2009-03-19

  Jorumycin, renieramycin, safracin and saframycin related compounds formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.
• Combination Therapy with an Antitumor Alkaloid
  申请人：Moneo Ocaña Victoria

  公开号：US20130266666A1

  公开（公告）日：2013-10-10

  The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer.